CoreCare
The AI platform for long-term and post-acute care
Published Aug 3, 2026
Public site and marketing materials provide limited detail on admin controls, permissioning, API capabilities, implementation timelines by integration type, and operational analytics definitions.
Public information does not document model performance metrics, error rates, or validation approaches for automated or machine-learning features. This is a common gap among vendors but is material for high-stakes workflows.
Depending on an organization’s existing EHR/EMR and vendor contracts, CoreCare may overlap with modules already provided by an EHR vendor (e.g., eligibility verification). ROI depends on whether CoreCare reduces work versus adding another operational layer.
The lack of accessible, verified reviews makes it harder to assess user adoption, support quality, uptime, and product maturity. Buyers should perform reference checks and contractually define SLAs.
Because independent review volume is low, churn reasons are not well documented publicly. Plausible churn drivers to validate during diligence include:
CoreCare is not broadly reviewed on major B2B software review sites in an accessible way during this research:
This limited review footprint constrains the ability to cite systematic end-user feedback.
The vendor’s site includes customer quotes, for example:
These testimonials are vendor-curated and not independently verified.
Press releases include partner/customer quotes referencing reduced manual work and improved PASRR tracking transparency, and referencing faster referral evaluation via the Pre-Admit product. These items are public relations statements rather than randomized or independently verified reviews.
A small number of lower-signal sources surfaced that contain reviews but have limited verification:
These sources should be treated cautiously and are not a substitute for validated reference checks.
Vendor materials and press releases consistently emphasize:
These are vendor-reported benefits; buyers should request empirical outcome data and references.
A vendor press release (July 9, 2025) states a rollout across multiple facilities and references rapid risk surfacing.
Critical evaluation:
A working ICP derived from public customer examples suggests mid-size to large multi-facility operators with an established corporate revenue cycle / business office function.
Get a comprehensive analysis of CoreCare including market position, competitive landscape, adoption trends, and peer benchmarks.
Download full report →A vendor press release (July 23, 2021) claims Creative Solutions (a Texas SNF operator) expanded across multiple facilities "without hiring additional AR staff" and attributes this to CoreCare automation. The release also references setup time and integration with several EMRs.
Critical evaluation:
A vendor press release (June 4, 2024) describes deployment of the vendor’s clinical reimbursement solution across a large group of facilities in response to MDS 3.0 changes. The release states benefits such as reduced manual reporting and improved efficiency.
Critical evaluation:
CoreCare is a B2B workflow platform targeted at post-acute and long-term care (PALTC) providers, particularly skilled nursing facilities (SNFs). The product focuses on revenue-cycle-adjacent operational workflows such as intake/referrals, admission compliance tasks (e.g., PASRR), clinical reimbursement and reporting (e.g., MDS tracking and related forms), and business-office eligibility/renewals tracking. The vendor positions the product as a consolidation layer intended to replace spreadsheets, manual portal navigation, and fragmented processes by providing a single workflow layer that integrates with EHR/EMRs and state Medicaid systems.
Core modules described by the vendor include:
The above module descriptions are vendor-provided functionality summaries.
The vendor has made strong platform claims in public materials (for example, claims such as "integrated workflow platform for LTC" or "trusted by thousands"). These should be treated as vendor marketing unless independently validated.